INBX logo

Inhibrx Biosciences (INBX) CAPEX

Annual CAPEX

$4.59 M
+$3.91 M+569.53%

December 31, 2023

Summary

Performance

1-Year Change

+569.53%

3-Year Change

+236.73%

5-Year Change

+221.41%

15-Year Change

+242.76%

INBX CAPEX Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

55.17%
INBX annual capital expenditures is higher than 55.17% of companies in Healthcare sector

High & Low

All-time High

$4.59 M
INBX annual capital expenditures is currently at an all-time high

3-Year Low

$686.00 K
INBX annual capital expenditures is currently +569.53% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
INBX previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Feb 28, 2025
INBX next annual earnings announcement is scheduled for Feb 28, 2025

OtherINBXcash flowmetrics:

Annual FCF

-$197.90 M
INBX annual free cash flow is -$197.90 million

Annual CFO

-$193.31 M
INBX annual cash flow from operations is -$193.31 million

Annual CFI

-$4.59 M
INBX annual cash flow from investing activities is -$4.59 million

Annual CFF

$201.96 M
INBX annual cash flow from financing activities is $201.96 million

Quarterly CAPEX

N/A

September 30, 2024

Summary

Performance

3-Month Change

-

1-Year Change

-

3-Year Change

-

5-Year Change

-

INBX Quarterly CAPEX Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$3.44 M
INBX quarterly capital expenditures is currently at an all-time high

3-Year Low

-$20.00 K
INBX quarterly capital expenditures is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
INBX previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 28, 2025
INBX next earnings announcement is scheduled for Feb 28, 2025

OtherINBXcash flowmetrics:

Quarterly FCF

-$30.53 M
INBX quarterly free cash flow is -$30.53 million

Quarterly CFO

-$30.28 M
INBX quarterly cash flow from operations is -$30.28 million

Quarterly CFI

-$247.00 K
INBX quarterly cash flow from investing activities is -$247.00 thousand

Quarterly CFF

$0.00
INBX quarterly cash flow from financing activities is $0.00

TTM CAPEX

N/A

September 30, 2024

Summary

Performance

3-Month Change

-

1-Year Change

-

3-Year Change

-

5-Year Change

-

INBX TTM CAPEX Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$6.59 M
INBX TTM capital expenditures is currently at an all-time high

3-Year Low

$587.00 K
INBX TTM capital expenditures is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
INBX previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 28, 2025
INBX next earnings announcement is scheduled for Feb 28, 2025

OtherINBXcash flowmetrics:

TTM FCF

-$149.23 M
INBX TTM free cash flow is -$149.23 million

TTM CFO

-$143.21 M
INBX TTM cash flow from operations is -$143.21 million

TTM CFI

-$6.02 M
INBX TTM cash flow from investing activities is -$6.02 million

TTM CFF

$4.18 M
INBX TTM cash flow from financing activities is $4.18 million

INBX CAPEX Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+569.5%--
3 y3 years+236.7%--
5 y5 years+221.4%--

INBX CAPEX Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+569.5%
5 y5-yearat high+569.5%
alltimeall timeat high+569.5%

Inhibrx Biosciences CAPEX History

DateAnnualQuarterlyTTM
Jun 2024
-
$1.22 M(+8.6%)
$6.59 M(+15.8%)
Mar 2024
-
$1.12 M(-67.5%)
$5.69 M(+23.9%)
Dec 2023
$4.59 M(+569.5%)
$3.44 M(+324.4%)
$4.59 M(+223.9%)
Sep 2023
-
$811.00 K(+155.8%)
$1.42 M(+141.6%)
Jun 2023
-
$317.00 K(+1278.3%)
$587.00 K(-0.8%)
Mar 2023
-
$23.00 K(-91.4%)
$592.00 K(-13.7%)
Dec 2022
$686.00 K(-20.6%)
$267.00 K(-1435.0%)
$686.00 K(0.0%)
Sep 2022
-
-$20.00 K(-106.2%)
$686.00 K(-21.6%)
Jun 2022
-
$322.00 K(+175.2%)
$875.00 K(-9.5%)
Mar 2022
-
$117.00 K(-56.2%)
$967.00 K(+11.9%)
Dec 2021
$864.00 K
$267.00 K(+58.0%)
$864.00 K(-28.5%)
Sep 2021
-
$169.00 K(-59.2%)
$1.21 M(-9.7%)
Jun 2021
-
$414.00 K(+2857.1%)
$1.34 M(+4.0%)
DateAnnualQuarterlyTTM
Mar 2021
-
$14.00 K(-97.7%)
$1.29 M(-5.6%)
Dec 2020
$1.36 M(-24.6%)
$612.00 K(+104.7%)
$1.36 M(+25.5%)
Sep 2020
-
$299.00 K(-17.4%)
$1.09 M(-27.5%)
Jun 2020
-
$362.00 K(+297.8%)
$1.50 M(-17.8%)
Mar 2020
-
$91.00 K(-72.8%)
$1.82 M(+0.8%)
Dec 2019
$1.81 M(+26.7%)
$335.00 K(-52.9%)
$1.81 M(+22.7%)
Sep 2019
-
$711.00 K(+3.5%)
$1.48 M(+93.1%)
Jun 2019
-
$687.00 K(+792.2%)
$764.00 K(+29.9%)
Mar 2019
-
$77.00 K(-84.9%)
$588.00 K(+0.3%)
Dec 2018
$1.43 M(+6.6%)
-
-
Jun 2018
-
$511.00 K(+581.3%)
$586.00 K(+681.3%)
Mar 2018
-
$75.00 K
$75.00 K
Dec 2017
$1.34 M
-
-

FAQ

  • What is Inhibrx Biosciences annual capital expenditures?
  • What is the all time high annual CAPEX for Inhibrx Biosciences?
  • What is Inhibrx Biosciences annual CAPEX year-on-year change?
  • What is the all time high quarterly CAPEX for Inhibrx Biosciences?
  • What is the all time high TTM CAPEX for Inhibrx Biosciences?

What is Inhibrx Biosciences annual capital expenditures?

The current annual CAPEX of INBX is $4.59 M

What is the all time high annual CAPEX for Inhibrx Biosciences?

Inhibrx Biosciences all-time high annual capital expenditures is $4.59 M

What is Inhibrx Biosciences annual CAPEX year-on-year change?

Over the past year, INBX annual capital expenditures has changed by +$3.91 M (+569.53%)

What is the all time high quarterly CAPEX for Inhibrx Biosciences?

Inhibrx Biosciences all-time high quarterly capital expenditures is $3.44 M

What is the all time high TTM CAPEX for Inhibrx Biosciences?

Inhibrx Biosciences all-time high TTM capital expenditures is $6.59 M